Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.

Sheng-Teng Huang

Status and phase

Completed

Phase 1

Conditions

Coronavirus Disease 2019

Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Treatments

Combination Product: Kang Guan Recipe (Treat)

Combination Product: Kang Guan Recipe (Placebo)

Study type

Interventional

Funder types

Other

Identifiers

NCT06291883

CHUH112-REC2-008

Details and patient eligibility

About

These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.

Full description

The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to present challenges despite widespread vaccination efforts, with breakthrough infections remaining a concern. This has led to increased interest in exploring alternative preventive measures, including dietary and natural product-based interventions. Previous studies have demonstrated the potential of herbal medicines in inhibiting viral infections and as therapies for COVID-19. Additionally, research has identified various herbal medicines with inhibitory properties against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, highlighting their potential in combating the virus. Here Researchers found that novel herbal medicine formula Kang Guan Recipe (KGR) is a potent inhibitor against SARS-CoV-2 viral infection. Researchers demonstrated that KGR showed inhibitory activity against variants of concern (VOCs) of SARS-CoV-2 infection. Moreover, they also found that KGR can block the interaction of viral Spike and human angiotensin-converting enzyme 2 (ACE2). Furthermore, Researchers assessed the inhibitory effect of KGR on SARS-CoV-2 viral entry in vivo and observed that serum samples from healthy human subjects exhibited suppressive activity against various SARS-CoV-2 variants after consuming KGR. These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.

Enrollment

26 patients

Sex

All

Ages

20 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy participants aged 20-60 with a body weight of over 50 kilograms.
Individuals who have never been diagnosed with COVID-19 or have recovered from COVID-19 for more than three months.
No consumption of any traditional Chinese medicine or food containing Chinese medicine within the preceding 36 hours before the experiment.
Vaccinated individuals who received their vaccine more than three months ago.
Willingness to undergo venous blood tests (approximately 10 cc of blood to be drawn three times).

Exclusion criteria

History of major internal medical conditions, including diabetes, hypertension, chronic obstructive pulmonary disease (COPD), asthma, abnormal liver function (AST levels exceeding 5 times the normal value), renal dysfunction (eGFR <60), cancer, etc.
Brain disorders such as trauma, stroke, tumors, epilepsy, or dementia.
Mental health disorders such as depression, anorexia nervosa, or schizophrenia.
Pregnant or lactating women. If there is suspicion of pregnancy, a commercial urine pregnancy test will be conducted.
Smokers, alcoholics, or betel nut addicts.
Inability to comply with the trial procedures.
Inability to sign the informed consent form.
Within three months of a confirmed COVID-19 diagnosis.
Within three months of receiving a vaccine shot.